TOTAL: $493.22M |
||||
Company | Type Of | Number Of | Amount | Investors; Placement Agents; Details (Date)@ ($M) |
Alliance Pharmaceutical Corp. (ALLP) | Debenture financing | | $10 | Alliance received $10M from the sale of subordinated convertible debentures to a small group of investors, who have the option to purchase an additional $10M of debentures convertible into stock at $16 per share for four years after issuance (8/22) |
Antisoma plc (UK; LSE:ASM) | Private Placement | 7.68S | #8.7 (US$13) | Antisoma raised #8.7M (US$13) by placing 7.68M shares at #1.17 per share, a discount of 8 percent to the July 26 closing price (7/27) |
Aviron (AVIR) | Private placement | 0.262S | $8 | Aviron sold 262,200 shares to Acqua Wellington Asset Management LLC for an aggregate price of $8M, or $30.51 per share; the company did not pay any fees in connection with the transaction (8/8) |
Bioject Medical Technologies Inc. (BJCT) | Equity financing | 1.4S | $10.5 | Bioject completed the final segment of a private equity financing with the sale of 150,000 shares at $7.88 per share, bringing the total financing to $10.5M net, represent- ing about 1.4M shares; Lone Pine Capital acted as the lead investor and five other investors participated (8/4) |
Caliper Technologies Corp. (CALP) | Private placement of common stock | 2.3S | $110.4 | Caliper sold 2.3M shares at $48 per share, representing a discount to market price (8/30) |
Cerus Corp. (CERS) | Private placement | 1.2S | $60 | Cerus raised $60M through the issuance of 1.2M shares at $50 per share (8/29) |
CombiMatrix Corp., majority- owned affiliate of Acacia Research Corp. (ACRI) | Private equity financing | | $36 | Investors included Acacia Research, Emerging Growth Management, JDS Capital, Oracle Partners, OrbiMed Advisors, SAC Capital Management, Seneca Capital and Wheatley Partners (8/3) |
Coulter Pharmaceutical Inc. (CLTR) | Private placement | 1.655S | $35.8 | Coulter entered into an agreement to sell 1.655M shares at $21.625 per share, raising $35.8M; Pacific Growth Equities Inc. served as the placement agent (8/14) |
CV Therapeutics Inc. (CVTX) | Common stock equity | | | CV received a commitment for up to $120M in common stock equity financing from Acqua Wellington North American Equities Fund Ltd.; CV may sell shares at its discretion and at a small discount to the market price over the next 28 months (8/8) |
Derma Sciences Inc. (DSCIC) | Private financing | 0.67U | $0.5 | Derma concluded an agreement with three investment firms to sell $500,000 of the company's Series E units at $0.75 per unit; the units consist of one share and 1.1 warrant to purchase one share at $0.85 per share; the warrants expire July 18, 2005; purchasers included Kensington Capital Management LLC, Dolphin Offshore Partners and Redwood Asset Management (8/23) |
Genelabs Technologies Inc. (GNLB) | Equity financing | 0.78S | $3.11 | Genelabs sold 779,271 shares to Acqua Wellington North American Equities Fund Ltd. for $3.99 per share; the company did not pay any fees in connection with the transaction (8/9) |
Immunex Corp. (IMNX) | Shelf registration | 70S | | Immunex filed for a shelf registration to sell up to 70M shares, 20M from the comp- any and 50M from American Home Products Corp., which holds 283.9M shares; terms will be determined at the time of the offering (8/9) |
Incara Pharmaceuticals Corp. (INCR) | Equity financing facility | | | Incara entered into a definitive agreement with Torneaux Fund Ltd. to sell stock over 15 months; the amount of the investment is dependent on Incara's stock price and is ex- pected to exceed $3M, but is capped at $18.9M (8/18) |
Interferon Sciences Inc. (OTCBB:IFSC) | Private placement of units | 11.64U | $7.7 | Interferon raised $7.7M from the sale of 11.64 units, which each contain one share of common stock and a warrant, exercisable until April 2005, to purchase one share at $1.50 (8/8) |
InterMune Pharmaceuticals Inc. (ITMN) | Private placement of stock | 2S | $76 | InterMune raised $76M through a private placement of 2M shares at $38 per share; Prudential Vector Healthcare Group was the lead placement agent; co-placement agents were Lehman Brothers and UBS Warburg LLC (8/17) |
Magainin Pharmaceuticals Inc. (MAGN) | Private placement | 4.1S | $12.4 | Magainin sold 4.1M shares at $3 per share, raising $12.4M; both existing and new in- vestors participated, including the State of Wisconsin Investment Board; Paramount Capital Inc. was financial adviser (8/11) |
Matritech Inc. (NMPS) | Equity financing | 2.45S | | Matritech entered into an agreement with Acqua Wellington North American Equities Fund Ltd. to sell over 14 months up to 2.45M shares that are part of a shelf registration; the shares may be sold at a small discount to market and the total investment is dependent on the company's stock price (8/24) |
Myriad Genetics Inc. (MYGN) | Equity placement | 0.175S | $22 | Myriad received $22M in a direct equity placement with Acqua Wellington North American Equities Fund Ltd.; the 175,000 shares were sold at a small discount to the market price (8/29) |
NeoRx Corp. (NERX) | Private placement | 2.45S | $37 | NeoRx sold 2.45M shares to institutional investors led by Lone Pine Capital LLC, Capital Research and Management Co., and Deerfield Management, raising $36M in net proceeds; following the offering, the company has 26M shares outstanding; Adams, Harkness & Hill Inc. acted as placement agent(8/29) |
NexMed Inc.(NEXM) | Private equity placement | 2.008S | $16.68 | NexMed sold 2.008M shares, raising $16.68M; investors paying $18 per unit received two shares at $9 per share and one warrant to purchase one share at $13.50; investors paying $16.54 per unit received two shares at $8.27 per share and one warrant to purchase 0.7 share at $13.50; all warrants may be exercised over the next 18 months; investors included Capital Research and Management Co. and a mutual fund managed by a major investment firm; AmeriCal Securities Inc. acted as the placement agent (8/2) |
NexMed Inc. (NEXM) | Private equity placement | 1.13S | $10.17 | NexMed sold an additional 1.13M shares, raising an additional $10.17M; investors paid $18 per unit and received two shares at $9 per share and one 18-month warrant to purchase one share at $16.20 per share; AmeriCal Securities Inc. and Shannon Limited acted as placement agents (8/9) |
Oxford Biomedica plc (UK; LSE:OXB) | Private placement of ordinary shares | 14.6S | #8.5 (US$12.8) | Oxford raised #8.5M through the issuance of 14.6M ordinary shares at 60 pence per share (8/10) |
Paracelsian Inc. (OTC:PRLN) | Private equity investment | | $0.5 | Paracelsian received an equity investment of $0.5M and also issued warrants that could result in an additional investment of $1.5M by Dec. 31 if the warrants are exercised in full (8/10) |
StemCells Inc. (STEM) | Private placement | 0.924S | $4 | StemCells completed a $4M common stock financing, receiving $3M at closing and will receive $1M more upon effectiveness of a reg- istration statement covering shares owned by the investment fund; the fund purchased the stock at $4.33 per share and will be entitled to receive additional shares on eight dates; the fund also has the option for 12 months to purchase up to $3M of additional common stock (8/7) |
Syn X Pharma Inc. (CDNX:SYY | Private placement of special warrants | | C$5.8 (US$3.9M) | Each warrant will be exercisable into one common share and one common share purchase warrant, which has a term of two years and entitles the holder to purchase one common share at C$4 in the first year and C$4.25 in the second year; 50 percent of proceeds go to Syn X and 50 percent will go in escrow pending the comp-any's achievement of two of six milestones; Octagon Capital Corp. and Thomson Kernaghan & Co. Ltd. led the placement (8/16) |
Vion Pharmaceuticals Inc. (VION) | Exercise of purchase options | 0.113U | $2.76 | Holders of Vion's remaining 113,333 unit purchase options exercised them, giving the company $2.76M and resulting in the issuance of 494,816 shares; Vion now has 25.96M shares outstanding (8/14) |
Notes: |
||||